• The 2009 guidelines based on actual body weight dosing did not confer any advantage in achieving therapeutic trough levels over conventional 1 gm every 12 hour dosing when applied to our patient population.
• There was no difference in the rate of nephrotoxicity between these dosing regimens.
• Patients with low and high BMIs may not be well-served by compliance with the current guidelines. In our obese patients there was a significantly high rate of supra-therapeutic troughs.
• Our findings are very consistent with Reynolds et al. who found similarly high rates of supra-therapeutic troughs and almost identical mean trough levels in their obese patients.
• Optimal vancomycin dosing is more complex for patients at extremes of weight and deserves further study.
• Implementation of the other aspects of the guidelines in addition to the actual dose of drug did result in more consistent vancomycin dosing and appropriately timed troughs levels compared to pre-guideline practices. 
RESULTS DISCUSSION
• ABW-dosing did not confer any benefit over conventional dosing when groups were compared overall.
• Having a guideline in place which specified dose, dosing interval and timing of trough resulted in far fewer patients being excluded for inconsistent dosing and inappropriatedly drawn troughs but compliance still not 100% • ABW-dosing was most effective in achieving therapeutic troughs in patients with BMIs between 20-24.9 but even in this group only 50% of the time • ABW-dosing was least effective at low and high BMI subgroups.
• ABW-dosing in pts with BMI ≥ 35 had 48% supra-therapeutic trough levels.
• In ABW-dosed patients with BMI ≥ 30, the mean supratherapeutic trough was 29. Results: There were no significant differences in therapeutic troughs and nephrotoxicity. Adjusted for BMI, there was a significant difference in trough levels between the two groups, P=0.0109. However, a large number of patients in the conventionally-dosed group were excluded due to inconsistent doses in the ABW-dosed group there was a high number of supratherapeutic trough levels Conclusion: Obese patients may require an alternate dosing strategy as the ABW-dosing based on the 2009 national guidelines resulted in supra-therapeutic levels in patients with high BMIs. Implementing guidelines -based monitoring resulted in more consistently and appropriately drawn levels.
National guidelines for vancomycin dosing recommend actual body weight (ABW) -dosing over conventional dosing regardless of BMI. The guidelines acknowledge limited data in obese patients. This study tested the applicability of the guidelines to our hospitalized patients with suspected or proven infections who represented a wide range of BMIs. The achievement of therapeutic trough levels using conventional dosing was compared to ABWdosing in obese and non-obese patients. The rate of nephrotoxicity in patients receiving conventional and ABW-dosing was also examined.
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• • Definitions: vancomycin levels: sub-therapeutic <10mg/L, therapeutic 10-20mg/L, supra-therapeutic >20mg/L. Nephrotoxicity was defined as an increase in serum creatinine level of 0.5mg/dL or an increase of 50% from baseline on at least two consecutive days during the period from start of vancomycin to 72 hrs after treatment completion. Obesity was defined as having a BMI of ≥ 30.
• Chi -square test (p<0.05) was used to show the difference between the 2008 and 2012 groups in achieving therapeutic trough levels , rates of nephrotoxicity and patient demographics . The JonckheereTerpstra test was used to compare differences in percentages of different trough groups (SAS, Cary, NC).
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